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rlakshmisuresh@gAbstract Duloxetine hydrochloride enteric coated pellets were formulated using ﬂuidized bed.
Three separate layers, the drug layer, the barrier layer, and the enteric layer, were coated onto the
inert core pellets. The pellets were optimized with the acid resistance and drug release in simulated
intestinal ﬂuid as the process parameters, using the Taguchi L9 orthogonal array. Various other
properties, such as surface morphology, bulk and tapped density, Hausner’s ratio, hardness,
friability, yield of pellets, moisture content, and particle size distribution, were also studied in the
optimized pellets. The concentration of the enteric polymer played a vital role in acid resistance,
while the type of enteric polymer affected the drug release in simulated intestinal ﬂuid. In both
cases, it was determined that binder polymer concentration was not affected much. The
comparisons between the optimized pellets and a market formulation yielded f1 and f2 values
within a range of 4–5 and 60–65, respectively. Three month stability studies, conducted at
accelerated conditions, showed the optimized pellets to be stable. Taguchi plays an important roleedica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association. Production and
rved.
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Table 1 Various parameters of
Sl. no. FBP variable
1. Inlet temperature (1C)
2. Outlet temperature (1C
3. Bed temperature (1C)
4. Peristaltic pump (rpm;
FBP—ﬂuidized bed processor.
Enteric coated pellets preparation and optimization using the Taguchi L9 design 57in optimizing parameters, and optimization of duloxetine hydrochloride can be achieved with
minimal trials.
& 2011 Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical
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Pellets, multi-unit dosage forms, have both therapeutic and
pharmaceutical advantages. Therapeutic advantages include
modiﬁcation of drug release, division of dose strength, and
free dispersion in the gastrointestinal tract when administered
orally. The pharmaceutical advantages include a high degree
of ﬂexibility in design and development during delivery of
incompatible bioactive agents due to the low surface area to
volume ratio compared to powders and granules. Therefore,
pellets serve as an excellent coating substrate and can be
incorporated into high amounts of actives without producing
an excessively large particle1.
Duloxetine hydrochloride ((þ)-(S)-N-methyl-g-(1-naphthy-
loxy)-2-thiophenepropylamine hydrochloride), a dual inhibitor
of serotonin and norepinephrine reuptake, has various thera-
peutic advantages in diseases such as major depressive disorder,
ﬁbromyalgia2, diabetic peripheral neuropathic pain3, premenstr-
ual disphoretic disorder4, phantom limb pain5, and male6 and
female7 stress incontinence. It is desirable to formulate this
multi-purpose drug in a more patient-compliant pellet form.
Since duloxetine hydrochloride is acid-labile, it degrades to
highly toxic compound 1-naphthol in acidic pH. Enteric
coating is preferred to prevent the acid degradation in the
stomach. However, duloxetine hydrochloride reacts with
enteric polymers like hydroxy propyl methyl cellulose acetate
succinate (HPMC AS) and hydroxy propyl methyl cellulose
phthalate (HPMC P) to form impurities like succinamide and
phthalamide8. A separating layer is coated to prevent the
impurity formation between the core and the surrounding
enteric polymer.
In this study, duloxetine hydrochloride pellets were given
three separate coatings, each of which formed the drug layer,
the barrier layer, and the enteric layer. Fluidized bed was used
to coat the three layers. The effects of various polymers, such
as enteric, barrier, and binder polymers, were analyzed.
Experimental design techniques such as Taguchi were used
to delineate the effect of each of these polymers on the ﬁnal
formulation and to optimize these product variables on the
ﬁnal pellet. The type of enteric polymer, concentration of
enteric polymer, concentration of barrier polymer, and con-
centration of binder polymer were studied and their effects onﬂuidized bed processor.
)
Electrolab PP-201V of 1.5 cm diamthe ﬁnal pellet were determined. We also monitored the release
of duloxetine hydrochloride in simulated gastric ﬂuid (SGF)
and simulated intestinal ﬂuid (SIF) without enzymes. Various
enteric polymers like HPMC phthalate and HPMC acetate
succinate both MG and MF grades were used.
2. Materials and methods
2.1. Materials
Duloxetine hydrochloride was purchased from Shodhana Labs
Ltd. (Andhra Pradesh, India). The polymers—hydroxy propyl
methyl cellulose acetate succinate MG (HPMC ASMG),
hydroxy propyl methyl cellulose acetate succinate MF (HPMC
ASMF), hydroxy propyl methyl cellulose phthalate (HPMC P)
and hydroxy propyl methyl cellulose E5 (HPMC E5)—were
obtained from SHIN-ETSU (Japan). Sodium lauryl sulfate was
from Stepan (USA), titanium dioxide was purchased from
Signet Chemical Corporation (Mumbai, India), and polyethy-
lene glycol 6000 (PEG 6000) was purchased from Clarient
Chemicals Ltd. (Thane, India). Solvents such as methylene
chloride and isopropyl alcohol were purchased from Rankem
Chemicals Ltd. (Andhra Pradesh, India). All the chemicals
used were of analytical grade.
2.2. Preparation of pellets
The pellets were prepared in a ﬂuidized bed processor (Umang
Pharmatech Pvt. Ltd.) by the solution or suspension layering
technique. During this technique, the solution containing drug
substances or polymers was deposited onto inert spheres.
Sugar spheres of 800 mm were given three coats or layers,
using ﬂuidized bed processor (Table 1). The sugar spheres
were loaded onto ﬂuidized bed and warmed before treatment
with drug solution. The high drying efﬁciency and the
proﬁcient Wurster process make this technique distinctive
from conventional pan coating.
HPMC E5 was used both as binding agent and barrier
polymer owing to its low molecular weight and its application
of acting as good pelletization aid9. HPMC P, HPMC ASMG,
and HPMC ASMF were the three selected enteric polymers.Drug layering Barrier layering Enteric layering
45 50 43
45 40 40
42 45 40
eter) 2 2 2
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HPMC E5, the binding polymer, was dissolved in isopropyl
alcohol with constant stirring. Methylene chloride was then
added slowly to the obtained solution. Duloxetine hydro-
chloride was incorporated intermittently into the solution with
constant stirring. The obtained solution was loaded onto the
sugar spheres.2.2.2. Barrier layer
The next layer was the barrier layer, also called the separating
layer, whose primary function was to minimize the interaction
between the drug and the enteric polymer. This layer also
provides a smooth base for the application of the enteric layer
and improves drug stability.
The barrier polymer, HPMC E5, was dissolved in water.
The surfactant Tween 80 was used to enhance the rounding off
capability10. Talc was used as an anti-adherent. The ratio of
binder polymer to surfactant to talc was maintained at
6:1:0.8. This ratio was optimized through preliminary studies.2.2.3. Enteric layer
HPMC P, HPMC ASMG, and HPMC ASMF were the
enteric polymers. Triethyl citrate was used as the plasticizer11.
Talc was used as an anti-adherent. The ratio of enteric
polymer to plasticizer to talc was maintained at 10:1:0.8. This
ratio was optimized through preliminary studies.2.3. Experimental design12–15
The Taguchi experimental design was selected to investigate the
effect of different parameters on the mean and variance of the
process performance and to obtain an optimal, well-functioning
process. In this design, orthogonal arrays arrange the affecting
parameters and their levels in the way, most likely to affect the
process. Unlike factorial design, where all the possible combina-
tions are tested, Taguchi employs a minimal number of trials
by testing pairs of combinations. This saves both time and
resources. The optimal parameters obtained from these trials are
insensitive to environmental changes and other noise factors.2.3.1. Optimization of process parameters
In the present study, the following four process parameters
were selected: type of enteric polymer, concentration of enteric
polymer, concentration of barrier polymer, and concentration
of binding polymer. Each of these parameters was of three
different levels, as stated in Table 2.
Four parameters, at three levels each, would give 81
experiments in the full factorial design (34). However, Taguchi
gave only nine experimental runs using the L9 orthogonal
array, as shown in Table 3. The sequence of the experimental
runs was randomized to prevent any bias.
As the pellets are enteric in nature, acid resistance and
release of drug in SIF at the end of 1 h were the two main
criteria that were assessed. SGF constituted about 0.1 mol/L
hydrochloric acid and SIF was 6.8 pH phosphate buffer.
These two variables were interpreted as responses when
optimizing the pellets. The values given in Table 4 are the
mean of three trials done at each set of experimental condi-
tions, and for each process variable.2.3.2. Conﬁrmatory test
After determining the optimal process parameters and their
affecting levels, experiments pertaining to these levels were
carried out.
2.3.3. Characterization of resultant pellets
The resultant pellets were tested for in vitro drug release behavior.
The pellets were also evaluated for surface morphology, bulk and
tapped density, Hausner’s ratio, hardness, friability, yield of
pellets, moisture content, and particle size distribution. The
evaluation was done in triplicates and the standard deviation
was calculated. Surface morphology was observed using scanning
electron microscopy (SEM). Bulk and tapped densities were
obtained using tapped density tester-USP (Electrolab-ETD
1020). Hardness was determined using texture analysis (TA;
XT; Plus, Texture Technologies, USA). Friability was tested
using a Roche friabilator (Erweka, Germany). 10 g of pellets and
25 glass spheres were centrifuged together for 10 min at 25 rpm.
After the test, the pellets were re-weighed and the weight loss was
calculated16. Moisture content was estimated using a Karl Fischer
instrument (Metrohm 787 KF Titrino). Sieve analysis was done
for particle size and distribution. 100 g of pellets was passed
through stacks of sieves of 710, 850, 1000, 1180, 1400, and
1700 mm.
The resultant pellets were compared with those of the
market formulation ‘‘CYMBALTA’’, and f1 and f2 values
were compared. The drug release pattern of the optimized
formulations was also recorded. The pellets were compared
after 15, 30, 45, 60, and 90 min in SIF (6.8 pH phosphate
buffer). The stability of the pellets formed at accelerated
conditions of 4072 1C and 7575% RH was also observed.
3. Results and discussion
The S/N ratio for larger-the-better characteristic was chosen
for both the acid resistance and release in phosphate buffer
since acid resistance and release in phosphate buffer should be
more as these factors are a primary requisite for a modiﬁed
drug release formulation. The S/N ratio of both responses is
given in Table 5. The mean of these S/N ratios at each level of
process variable or affecting factor is summarized in Table 6
and Fig. 1.
The ranks obtained for each factor will determine its effect
on the drug release pattern of the pellets. Table 6 shows that
the concentration of enteric polymer plays a primary role in
acid-resistant pellets since there was an increased resistance to
acid with an increase in the concentration of the enteric
polymer. The type of enteric polymer also plays a role in
resistance to acidity, which suggests that enteric polymers have
varied resistance to acids. Pellets with good release at the end
of 1 h in SIF were mostly affected by the type of enteric
polymer since polymers dissolve at different pH’s. The extent
of dissolution depends on the degree of ionization, which is the
guiding parameter. The polymer should be ionized to be
dissolved. Once the enteric polymer gets dissolved, the barrier
polymer is another factor affecting drug release patterns since
it is the next layer that obstructs the drug release. Therefore,
an increase in the concentration of the barrier polymer
increases the extent of obstruction of drug release. The
concentration of the binding polymer did not affect acid
resistance or the release in phosphate buffer.
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optimization of the pellets12. Based on this, as depicted in Table 6,
it can be concluded that the pellets would be optimized for acid
resistance when the processing conditions are A2B3C2D1 and
A3B3C1D2. A2B3C2D1 represents HPMC ASMG as the enteric
polymer at 30%, HPMC E5 as the barrier polymer at 10%, and
HPMC E5 as the binding polymer at 2.5% for the release in
phosphate buffer. A3B3C1D2 represents the enteric polymer
HPMC ASMF at 30%, the barrier polymer HPMC E5 at 5%,
and the binder polymer HPMC E5 at 3% for the release in
phosphate buffer.
Table 6 suggests that the best acid resistance is given by
HPMC ASMG while the best release in phosphate buffer isTable 2 Process parameters with their respective levels.
Process parameter Factor assigned
Type of enteric polymer A
Concentration of enteric polymer (%) B
Concentration of barrier polymer (%) C
Concentration of binder polymer (%) D
Table 3 Various trials to be carried out according to L9 orthog
Run Factor A (type of enteric
polymer)
Factor B (concentratio
of enteric polymer (%)
1 HPMC P 20
2 HPMC P 25
3 HPMC P 30
4 HPMC ASMG 20
5 HPMC ASMG 25
6 HPMC ASMG 30
7 HPMC ASMF 20
8 HPMC ASMF 25
9 HPMC ASMF 30
Figure 1 Graphs showinggiven by HPMC ASMF though the difference in S/N values is
not much striking. HPMC ASMG provides the best acid
resistance, which may be due to its granular structure and
large particle size (1000 mm).
HPMC ASMF, on the other hand, has a ﬁne structure with a
particle size of 5 mm. Additionally, Thoma et al.16 have reported
that the degree of micronization of the polymer affects the drug
release, which was improved by reducing the particle size of the
polymer. The ﬁne structure of HPMC ASMF allows it to
diffuse out due to penetration of the phosphate buffer medium;
furthermore, the particles do not agglomerate due to their
partial ionization charges17. These charge properties allow the
polymer particles to exist as individual entities, thereby favoringLevel 1 Level 2 Level 3
HPMC P HPMC ASMG HPMC ASMF
20 25 30
5 10 12
2.5 3 4
onal array.
n
)
Factor C (concentration
of barrier polymer (%))
Factor D (concentration
of binder polymer (%))
5 2.5
10 3
12 4
10 4
12 2.5
5 3
12 3
5 4
10 2.5
signal to noise ratios.
Table 5 Signal to noise ratios of the responses.
Experimental
run
S/N ratio
Acid resistance Phosphate
buffer release
1 39.6905 37.6948
2 39.9390 37.2676
3 40.1293 37.1840
4 39.9739 39.1051
5 40.1122 38.4649
6 40.3657 39.6364
7 39.9039 39.0365
8 40.0260 39.3697
9 40.4321 39.2047
Table 6 Mean of S/N ratios at each individual level.
Level Acid resistance Phosphate buffer release
A B C D A B C D
1 39.92 39.86 40.03 40.08 37.38 38.61 38.90 38.45
2 40.15 40.03 40.11 40.07 39.07 38.37 38.53 38.65
3 40.12 40.31 40.05 40.04 39.20 38.67 38.23 38.55
Delta 0.23 0.45 0.09 0.04 1.82 0.31 0.67 0.19
Rank 2 1 3 4 1 3 2 4
Table 4 Responses based on which the factors are
optimized.
Experimental
run
Acid resistance
(%)
Release in phosphate
buffer after 1 h (%)
1 76.69 96.5
2 73.01 99.3
3 72.31 101.5
4 90.21 99.7
5 83.8 101.3
6 95.9 104.3
7 89.5 98.9
8 93.0 100.3
9 91.25 105.1
Figure 2 SEM photographs of the formulated pellets.
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ASMF gave the best release in the phosphate buffer since its
smaller particle size may degrade easily in SIF.
The ideal concentration of the HPMC E5 barrier polymer
for drug release in SIF was 5%, the minimal quantity proposed.
These pellets were formulated and evaluated for various tests,as listed in Table 7. Since Hausner’s ratio is below 1.25, the
resultant pellets with the optimized concentrations of affecting
factors showed good ﬂow properties, as displayed in Table 7.
Friability values ofo1% suggest that the pellets have sufﬁcient
hardness. Sieve analysis showed that 8.9%, 80%, and 9.3% of
pellets were of 1000, 1180 and 1400 mm, respectively. This high
yield suggests that the processing variables optimized via
Taguchi are ideal to develop generic versions of the drug.
The resultant pellets were also compared with the market
formulation ‘‘CYMBALTA’’. Additionally, f1 and f2 values
were compared, as listed in Table 8. Since f1 and f2 values are
within the limits of 0–15 and 50–100, respectively, the
similarity between the experimental and the marketed for-
mulation was found to be 64.75% for acid resistance and
63.80% for SIF release in optimized pellets. The dissimilarities
in acid resistance and SIF release were found to be below 5%
(4.95% and 4.36%, respectively) in optimized pellets, suggest-
ing that the experimental formulation is ideal for carrying out
bioavailability and bioequivalence studies.
The optimized pellets (Fig. 2) have a minimal amount of
barrier concentration to maximize drug release since the drug
permeability from the core to the enteric layer via the barrier
layer is increased when the concentration of the barrier
polymer is low. Migration stability studies were carried out
to afﬁrm the stable drug release in SIF past the barrier layer.
The release pattern of both the acid-resistant optimized
samples as well as the phosphate buffer release optimized
samples followed the Korsmeyer Peppas pattern, which is
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patterns are given in Table 9.
Mean dissolution time (MDT) is useful in characterizing the
drug retarding efﬁciency of the polymer. Higher MDT values
were observed in the acid-resistance optimized pellets, suggestingTable 8 Dissolution data comparison with marketed formulatio
Dissolution media Time interval (min) Marketed formu
0.1 mol/L HCl At the end of 2 h 98.7
P-B 6.8 pH 15 45.10
30 77.90
45 86.50
60 92.90
90 95.90
f1 (0–15)
f2 (50–100)
A-R optimized—optimized acid-resistant pellets; P-B optimized—optim
Table 10 Stability report of A-R optimized formulation.
Test Speciﬁcation
Description White to off-white spherical pellets
Identiﬁcation Retention peak similar to that of standard
Water content (%) NMT 2.5%
Acid resistance (%) NLT 90%
P-B release (%) NLT 70%
Assay (%) NLT 90% and NMT 110% of label claim
Table 9 Korsemeyer Peppas drug release pattern.
Pellets type Regression coef
Marketed ‘CYMBALTA’ pellets 0.986
A-R optimized pellets 0.996
P-B optimized pellets 0.978
nMean dissolution time (MDT) was calculated in triplicate and stan
Table 7 Characterization of optimized pellets.
Characterization
parameter
Optimized pellet
A-R optimized P-B optimized
Bulk densityn (g/mL) 0.870.003 0.870.001
Tapped densityn (g/mL) 0.870.006 0.870.003
Hausner’s ratio 1.007 1.017
Friability indexn (%) 0.470.015 0.470.017
Hardnessn (kg) 7.570.251 7.470.264
Yield of pellets (%) 96.2 94.5
Moisture contentn (%) 1.070.026 1.370.080
A-R optimized—optimized acid-resistant pellets; P-B optimi-
zed—optimized release in phosphate buffer.
nCharacterization parameters were done in triplicate and
standard deviation was calculated.that the drug retarding efﬁciency of the acid-resistant pellets is
higher compared to that of phosphate buffer optimized pellets.
Stability studies, as shown in Tables 10 and 11, were carried
out for three months at accelerated conditions of 4072 1C and
7575% relative humidity (RH). These results suggest that
there is no such migration of drug from the core to the enteric
layer. The pellets were further checked for various impurities
as listed in Table 12, which suggests that incorporation of
barrier layer in between drug core and the surrounding enteric
polymers will retard the degradation reaction.
The impurity proﬁle data, as shown in Table 12, conﬁrms
the stability of the duloxetine.4. Conclusions
It is preferable to ﬁnd optimized formulations of duloxetine
hydrochloride using experimental design like Taguchi, which
not only reduce time but also provide ideal formulation. It is
important to consider various types of enteric polymers as well as
their concentrations, in addition to employing other polymers
during drug packaging. From the Taguchi analysis, the pellets
consisting of 30% enteric polymer (HPMC ASMG), 10% barriern ‘CYMBALTA’.
lation (%) A-R optimized (%) P-B optimized (%)
99.1 98.5
36.10 44.40
78.90 87.70
87.40 95.30
89.50 96.60
90.50 98.10
4.95 4.36
64.75 63.80
ized release in phosphate buffer.
A-R
Initial 1st month 2nd month 3rd month
Complies Complies Complies Complies
Complies Complies Complies Complies
1.01 1.52 1.59 1.69
98.5 98.6 97.4 96.0
89.5 88.6 87.4 85.0
101.7 99.6 91.5 87.1
ﬁcient ‘n’ value MDTn
0.41 0.6970.1
0.51 1.270.2
0.43 0.7070.1
dard deviation was calculated.
Table 12 Impurity proﬁle data.
Test Limit Day 0 1st month 2nd month 3rd month
Description Creamy white
collared
spherical pellets
Creamy white
collared
spherical pellets
Creamy white
collared
spherical pellets
Creamy white
collared
spherical
pellets
Moisture content (%) Not more than
4.0%
2.4 2.34 2.37 2.38
Assay (%) 90–110% 103.1 103.6 104.1 101
Related substances
Impurity A NMT 0.5% ND ND ND ND
Impurity C (%) NMT 0.5% 0.01 0.02 0.02 0.03
Impurity D (%) NMT 0.5% 0.04 0.05 0.01 0.01
Any individual unknown
impurity (%)
NMT 0.2% 0.05 0.06 0.10 0.08
Total impurities (%) NMT 1.5% 0.16 0.22 0.26 0.26
Dissolution
Acid resistance (%) NLT 90% of
labeled amount
of duloxetine HCl
shall retain
as residue after 2
hrs.
100.80 102.40 105.80 102.80
Dissolution in phosphate
buffer at pH 6.8 (%)
NLT 75% of
labeled amount
of duloxetine HCl
shall dissolve
in pH 6.8 buffer in
60 minutes.
94.80 94.50 97.50 102.60
Table 11 Stability report of P-B optimized formulation.
Test Speciﬁcation P-B
Initial 1st month 2nd month 3rd month
Description White to off-white spherical pellets Complies Complies Complies Complies
Identiﬁcation Retention peak similar to that of standard Complies Complies Complies Complies
Water content (%) NMT 2.5 1.32 1.82 1.89 1.99
Acid resistance (%) NLT 90% 99.1 98.6 95.9 91.0
P-B release (%) NLT 70% 96.6 93.6 91.4 89.1
Assay (%) NLT 90% and NMT 110% of label claim 101.7 98.3 95.5 87.1
Acid resistance at the end of 2 h in (SGF) 0.1 mol/L HCl; P-B release at the end of 1 h in (SIF) 6.8 pH phosphate buffer.
D. Shravani et al.62polymer (HPMC E5), and 2.5% binding polymer (HPMC E5)
were optimized for acid resistivity. The pellets containing 30%
enteric polymer (HPMC ASMF), 5% barrier polymer (HPMC
E5), and 3% binding polymer (HPMC E5) were optimized for
release in SIF. Both these optimized formulations were compared
favorably with the brand name formulation (Cymbalta), and gave
desirable f1 and f2 values. Therefore, this study shows that there is
a positive scope to further scale up the formulation of duloxetine
hydrochloride, and to develop a generic version of the drug.Acknowledgments
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